Spectris plc: Director/PDMR Shareholding
This notification is made under Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").
On 4 April 2025, Spectris plc (the "Company") was notified that Derek Harding, President, Spectris Scientific, had acquired 4,796 ordinary shares, with a total aggregate price of £99,986.05 on 4 April 2025.
The form for these transactions, as required under MAR, follow:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| a) | Name | Derek Harding | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Director/PDMR | ||
| b) | Initial notification/Amendment | Initial Notification | ||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Spectris plc | ||
| b) | LEI | 213800Z4CO2CZO3M3T10 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5p each
| ||
| b) | Nature of the transaction | Purchase of 3,741 shares at a price of £20.85 per ordinary share and 1,055 shares at a price of £20.84 per ordinary share.
| ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| £20.85 | 3,741 ordinary shares | |||
| £20.84 | 1,055 ordinary shares | |||
| d) | Aggregated information | Aggregated Volume | 4,796 | |
| Total Aggregate Price | £99,986.05 | |||
| e) | Date of the transaction | 4 April 2025 | ||
| f) | Place of the transaction | London Stock Exchange: LON | ||
Name of contact and telephone number for queries:
Harriet Huband
Head of Secretariat
Tel: +44 75541 97627
For and on behalf of Spectris plc
LEI Number: 213800Z4CO2CZO3M3T10
Date: 4 April 2025
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
